Oral diindolylmethane (DIM): Pilot evaluation of a nonsurgical treatment for cervical dysplasia



      Standard surgical treatment for CIN may impair fertility generating a need for alternative treatment options. We tested the efficacy and toxicity of oral DIM in the treatment of CIN 2 or 3 lesions.


      Patients with biopsy-proven cervical intraepithelial neoplasia (CIN) 2 or 3 scheduled for loop electrosurgical excision procedure (LEEP) were randomized 2:1 to receive diindolylmethane (DIM) (BioResponse-DIM®, BioResponse, Boulder, CO) orally at approximately 2 mg/kg/day for 12 weeks or placebo (defatted rice bran, BioResponse). Subjects were evaluated every 3–4 months for 1 year. Analysis of data up to 1 year was assessed including Pap smear, HPV, colposcopy, biopsy and physical examination were performed at follow-up. Central pathology review confirmed all histology diagnoses.


      To date, 64 subjects (mean age 28 years, range 18–61) have been enrolled (45 in the DIM arm, 19 in the placebo arm), with 60 available for analysis. Average follow-up was 6 months. At enrollment, 58% were diagnosed with CIN 2 and 42% with CIN 3, 57% of subjects were Caucasian, 15% African American, 12% Hispanic and 17% Asian. During treatment 2 subjects (3%) complained of nausea (grade 2) at the 3- to 4-month visit. No systemic toxicities were observed (normal CBC, LFTs, comprehensive metabolic). Forty-six subjects had biopsies at first follow-up (77%). Twenty-one subjects (47%) in the DIM group had improved CIN with a decrease by 1–2 grades or a normal result. Median time to improvement was 5 months. Improved Pap smear was seen in 49% (22/45) with either a less severe abnormality or normal result. Colposcopy improved in twenty-five subjects in the DIM group (56%). Of these 25 subjects, 21 (84%) had improved colposcopic impression, 13 (52%) had a decrease in involved quadrants and 18 (72%) had a decrease in lesion number. Complete colposcopic response was observed in 4 subjects (9%). Stratifying by level of dysplasia, age, race, HPV status, tobacco use, contraceptive used did not alter the results. At median follow-up of 6 months, 85% of subjects have not required LEEP based on routine clinical triage of improving global assessment. There was no statistically significant difference in any outcome between the DIM and placebo group.


      Oral DIM at 2 mg/kg/day is well tolerated with no significant toxicity. We observed a high rate of clinically significant improvement in confirmed CIN 2 or 3 lesions among both treatment groups in this randomized clinical trial.


      To read this article in full you will need to make a payment


      Subscribe to Gynecologic Oncology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


      1. National Cancer Institute. U.S. National Institutes of Health (

      2. Johns Hopkins University and Health System (

        • Montz F.J.
        Impact of therapy for cervical intraepithelial neoplasia on fertility.
        Am. J. Obstet. Gynecol. 1996; 175: 1129-1136
        • Forsmo S.
        • Hansen M.H.
        • Jacobsen B.K.
        • Oian P.
        Pregnancy outcome after laser surgery for cervical intraepithelial neoplasia.
        Acta Obstet. Gynecol. Scand. 1996; 75: 139-143
        • El-Bastawissi A.Y.
        • Becker T.M.
        • Daling J.R.
        Effect of cervical carcinoma in situ and its management on pregnancy outcome.
        Obstet. Gynecol. 1999; 93: 207-212
      3. Surveillance Epidemiology and End Results. Cancer Stat Fact Sheets. (

        • Dalessandri K.M.
        • Firestone G.L.
        • Fitch M.D.
        • Bradlow H.L.
        • Bjeldanes L.F.
        Pilot study: effect of 3,3′-diindolylmethane supplements on urinary hormone metabolites in postmenopausal women with a history of early-stage breast cancer.
        Nutr. Cancer. 2004; 50: 161-167
        • Chen D.Z.
        • Qi M.
        • Auborn K.J.
        • Carter T.H.
        Indole-3-carbinol and diindolylmethane induce apoptosis of human cervical cancer cells and in murine HPV16-transgenic preneoplastic cervical epithelium.
        J. Nutr. 2001 Dec; 131: 3294-3302
        • Savino J.A.
        • Evans J.F.
        • Rabinowitz D.
        • Auborn K.J.
        • Carter T.H.
        Multiple, disparate roles for calcium signaling in apoptosis of human prostate and cervical cancer cells exposed to diindolylmethane.
        Mol. Cancer Ther. 2006; 5: 556-563
        • Mogensen S.T.
        • Bak M.
        • Dueholm M.
        • Frost L.
        • Knoblauch N.O.
        • Praest J.
        • Svanholm H.
        Cytobrush and endocervical curettage in the diagnosis of dysplasia and malignancy of the uterine cervix.
        Acta Obstet. Gynecol. Scand. 1997; 76: 69-73
        • Bell M.C.
        • Crowley-Nowick P.
        • et al.
        Placebo Controlled Trial of Indole-3-Carbinol in the treatment of CIN.
        Gynecol. Oncol. 2000; 78: 123-129
        • Meyskens Jr, F.L.
        • Surwit E.
        • et al.
        Enhancement of regression of cervical intraepithelial neoplasia II (moderate dysplasia) with topically applied all-trans-retinoic acid: a randomized trial.
        J. Natl. Cancer Inst. 1994; 86 (6): 539-543
        • Platz C.E.
        • Benda J.A.
        Female genital tract cancer.
        Cancer. 1995; 75: 270-294
        • Vassilakos P.
        • Griffin S.
        • Megevand E.
        • Campana A.
        CytoRich liquid-based cervical cytologic test. Screening results in a routine cytopathology service.
        Acta Cytol. 1998; 42: 198-202
        • Gurski K.J.
        • Del Priore G.
        Gynecologic malignancies.
        in: Illig K Cowles Husser W The Rochester Manual: Practical Patient Care. Laennec Publishing, Cedar Grove, N.J1997
      4. American Cancer Society. Press Room. (

      5. University of Maryland Medical Center (

        • Wright Jr, T.C.
        • Cox J.T.
        • Massad L.S.
        • Twiggs L.B.
        • Wilkinson E.J.
        ASCCP-sponsored consensus conference. 2001 Concensus Guidelines for the management of women with cervical cytological abnormalities.
        JAMA. 2002; 287: 2120-2129
        • Hoffman M.S.
        • Martino M.A.
        2001 consensus guidelines for the management of women with cervical intraepithelial neoplasia.
        Am. J. Obstet. Gynecol. 2004; 191: 1049
        • Del Priore G.
        • Lee M.J.
        • Barnes M.
        • Garcia P.
        • Till M.
        The inadequacy of standard treatment of dysplasias in a woman with acquired immune deficiency syndrome.
        Int. J. Gynaecol. Obstet. 1999; 47: 273-274
        • Young J.L.
        • Jazaeri A.A.
        • Darus C.J.
        • Modesitt S.C.
        Cyclooxygenase-2 in cervical neoplasia: A review.
        Gynecol. Oncol. 2008; 109: 140-145
        • Safe S.
        • Wargovich M.J.
        • Lamartiniere C.A.
        • Mukhtar H.
        Symposium on mechanisms of action of naturally occurring anticarcinogens.
        Toxicol. Sci. 1999; 52: 1-8
        • Katdare M.
        • Osborne M.P.
        • Telang N.T.
        Inhibition of aberrant proliferation and induction of apoptosis in pre-neoplastic human mammary epithelial cells by natural phytochemicals.
        Oncol. Rep. 1998; 5: 311-315
        • Chen I.
        • McDougal A.
        • Wang F.
        • Safe S.
        Aryl hydrocarbon receptor-mediated antiestrogenic and antitumorigenic activity of diindolylmethane.
        Carcinogenesis. 1998; 19: 1631-1639
        • Stresser D.M.
        • Bjeldanes L.F.
        • Bailey G.S.
        • Williams D.E.
        The anticarcinogen 3,3′-diindolylmethane is an inhibitor of cytochrome P-450.
        J. Biochem. Toxicol. 1995; 10: 191-201
        • Cover C.M.
        • Hsieh S.J.
        • Cram E.J.
        • Hong C.
        • Riby J.E.
        • Bjeldanes L.F.
        • Firestone G.L.
        Indole-3-carbinol and tamoxifen cooperate to arrest the cell cycle of MCF-7 human breast cancer cells.
        Cancer Res. 1999; 15: 1244-1251
        • Broadbent T.A.
        • Broadbent H.S.
        The chemistry and pharmacology of indole-3-carbinol (indole-3- methanol) and 3-(methoxymethyl) indole.
        Med. Chem. 1998; 5: 469-491
        • Newfield L.
        • et al.
        Estrogen metabolism and human papillomavirus-induced tumors of the larynx: chemo-prophylaxis with indole-3-carbinol.
        Anticaric Res. 1993; 13: 337-342
        • Rosen C.
        • et al.
        Preliminary results of the use of indole-3-carbinol for recurrent respiratory papillomatosis.
        Otolaryngol. Head Neck Surg. 1998; 118: 810-815
      6. National Cancer Institute

        • Verschoyle R.D.
        • Greaves P.
        • Cai H.
        • Edwards R.E.
        • Steward W.P.
        • Gescher A.J.
        Evaluation of the cancer chemopreventive efficacy of rice bran in genetic mouse models of breast, prostate and intestinal carcinogenesis.
        Br. J. Cancer. 2007; 96: 248-254
        • Long N.K.
        • Makita H.
        • Yamashita T.
        • Toida M.
        • Kato K.
        • Hatakeyama D.
        • Shibata T.
        Chemopreventive effect of fermented brown rice and rice bran on 4-nitroquinoline 1-oxide-induced oral carcinogenesis in rats.
        Oncol. Rep. 2007; 17: 879-885
        • Pretorius R.G.
        • Belinson J.L.
        • Zhang W.H.
        • Burchette R.J.
        • Elson P.
        • Qiao Y.L.
        The colposcopic impression. Is it influenced by the colposcopist's knowledge of the findings on the referral Papanicolaou smear.
        J. Reprod. Med. 2001; 46: 724-728
        • Reed G.A.
        • Arneson D.W.
        • Putnam W.C.
        • Smith H.J.
        • Gray J.C.
        • Sullivan D.K.
        • Mayo M.S.
        • Crowell J.A.
        • Hurwitz A.
        Single-dose and multiple-dose administration of indole-3-carbinol to women: pharmacokinetics based on 3,3′-diindolylmethane.
        Cancer Epidemiol. Biomarkers Prev. 2006; 15: 2477-2481
        • Reed G.A.
        • Sunega J.M.
        • Sullivan D.K.
        • Gray J.C.
        • Mayo M.S.
        • Crowell J.A.
        • Hurwitz A.
        Single-dose pharmacokinetics and tolerability of absorption-enhanced 3,3′-diindolylmethane in healthy subjects.
        Cancer Epidemiol. Biomarkers Prev. 2008; 17: 2619-2624